Replimune is laying off 63 employees just days after the U.S. Food and Drug Administration rejected its melanoma therapy for a second time. The workforce reduction comes as the company faces significant regulatory hurdles for its lead development program.
According to BioPharma Dive, the agency's decision marks the second refusal for the firm's drug candidate. The therapy is designed to treat melanoma, a serious form of skin cancer. No specific details regarding the reasons for the rejection or the drug's clinical data were provided in the source article.